Comparative Pharmacology
Head-to-head clinical analysis: SODIUM OXYBATE versus XYROSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM OXYBATE versus XYROSA.
SODIUM OXYBATE vs XYROSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-hydroxybutyrate (GHB) receptor agonist; modulates GABA-B and GHB receptors, increasing slow-wave sleep and reducing cataplexy.
XYROSA is a fixed-dose combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. Sacubitril inhibits neprilysin, increasing natriuretic peptides and other vasoactive peptides, leading to vasodilation, natriuresis, and inhibition of fibrosis. Valsartan blocks the angiotensin II type 1 receptor, reducing vasoconstriction, aldosterone release, and cardiac remodeling.
Oral: 4.5 g to 9 g per day divided into two equal doses of 2.25 g to 4.5 g taken at bedtime and again 2.5 to 4 hours later. Maximum single dose: 4.5 g, maximum total daily dose: 9 g.
1.5 mg/kg IV once weekly; maximum 100 mg per dose.
None Documented
None Documented
Clinical Note
moderateSodium oxybate + Venlafaxine
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Venlafaxine."
Clinical Note
moderateSodium oxybate + Nefazodone
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Nefazodone."
Clinical Note
moderateSodium oxybate + Sertraline
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Sertraline."
Clinical Note
moderate0.5–1 hour; clinical context: rapid elimination necessitates multiple nightly doses in narcolepsy.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal; >80% of dose excreted as carbon dioxide via expiration, <5% unchanged in urine; minor fecal elimination.
Primarily renal excretion of unchanged drug (~60%) and glucuronide metabolite (~30%); biliary/fecal elimination accounts for <10%.
Category D/X
Category C
CNS Depressant
CNS Depressant / Narcolepsy Agent
Sodium oxybate + Paroxetine
"The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Paroxetine."